JIANGSU HENGRUI MEDICINE CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 44.75 CNY | +0.13% |
|
-4.58% | -1.06% |
| May. 16 | Hengrui Pharmaceuticals Plans Up to 1.2 Billion Yuan Share Buyback | MT |
| May. 15 | Jiangsu Hengrui Medicine Co., Ltd. announces an Equity Buyback for CNY 1,200 million worth of its shares. | CI |
ETFs positioned on Jiangsu Hengrui Medicine Co., Ltd.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 105 M€ | +4.03% | - | |
| 0.00% | 17 M€ | +3.53% | - | |
| 0.00% | 15 M€ | +18.83% | ||
| 0.00% | 54 M€ | +1.01% | - | |
| 0.00% | 8 M€ | +1.24% | - |
Jiangsu Hengrui Medicine Co., Ltd. specializes in the research, development, manufacture and marketing of pharmaceutical products. The activity is organized primarily around 5 families of products:
- anti-tumor drugs (No. 1 Chinese);
- Anesthetic drugs;
- contrast agents: used in medical imaging;
- anti-inflammatory drugs;
- drugs for the treatment of cardiovascular diseases.
Sector
Pharmaceuticals
Calendar
2024-08-18
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
44.75
CNY
Average target price
57.33
CNY
Spread / Average Target
+28.12%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -1.06% | 39.36B | |
| +32.09% | 694B | |
| +29.39% | 593B | |
| -1.34% | 371B | |
| +20.34% | 331B | |
| +7.39% | 290B | |
| +14.25% | 239B | |
| -3.03% | 209B | |
| +10.02% | 209B | |
| +8.49% | 169B |
- Stock Market
- Equities
- 600276 Stock
- Funds and ETFs Jiangsu Hengrui Medicine Co., Ltd.